Potential bias in observational PCSK9 inhibitor study.
作者信息
Blais Joseph Edgar, Wong Angel Y S
机构信息
Department of Pharmacology and Pharmacy, Centre for Safe Medication Practice and Research, LKS Faculty of Medicine, The University of Hong Kong, L2-54 Laboratory Block, 21 Sassoon Road, Pokfulam, Hong Kong SAR, China.
Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK.
出版信息
Eur Heart J Cardiovasc Pharmacother. 2025 Aug 12;11(5):483-484. doi: 10.1093/ehjcvp/pvaf041.
Abstract
摘要
相似文献
1
Potential bias in observational PCSK9 inhibitor study.观察性PCSK9抑制剂研究中的潜在偏倚。
Eur Heart J Cardiovasc Pharmacother. 2025 Aug 12;11(5):483-484. doi: 10.1093/ehjcvp/pvaf041.
2
Effect of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors on Lipid Profile and Cardiovascular Events in High-Risk Diabetic Patients.前蛋白转化酶枯草溶菌素/克新9型（PCSK9）抑制剂对高危糖尿病患者血脂水平及心血管事件的影响
Cureus. 2025 Jun 18;17(6):e86310. doi: 10.7759/cureus.86310. eCollection 2025 Jun.
3
Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin Intolerance.PCSK9抑制剂和英克西兰对神经肌肉疾病和他汀类药物不耐受患者的安全性和有效性
Eur J Neurol. 2025 Jun;32(6):e70175. doi: 10.1111/ene.70175.
4
A novel small-molecule PCSK9 inhibitor E28362 ameliorates hyperlipidemia and atherosclerosis.一种新型小分子 PCSK9 抑制剂 E28362 可改善血脂异常和动脉粥样硬化。
Acta Pharmacol Sin. 2024 Oct;45(10):2119-2133. doi: 10.1038/s41401-024-01305-9. Epub 2024 May 29.
5
PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis.PCSK9 抑制剂联合或不联合他汀类药物与依折麦布用于心血管风险降低的治疗：一项系统评价和网络荟萃分析。
BMJ. 2022 May 4;377:e069116. doi: 10.1136/bmj-2021-069116.
6
PCSK9 inhibitor improved cardiac function after acute myocardial infarction in rats.前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂改善了大鼠急性心肌梗死后的心脏功能。
Microvasc Res. 2025 Nov;162:104847. doi: 10.1016/j.mvr.2025.104847. Epub 2025 Jul 24.
7
PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.PCSK9 抑制剂和依折麦布降低心血管事件风险的临床实践指南：基于风险分层的推荐意见。
BMJ. 2022 May 4;377:e069066. doi: 10.1136/bmj-2021-069066.
8
Treatment persistence, lipid lowering, and 3-year clinical outcomes in patients at very high cardiovascular risk on PCSK9 monoclonal antibodies.接受前蛋白转化酶枯草溶菌素9（PCSK9）单克隆抗体治疗的极高心血管风险患者的治疗持续性、血脂降低情况及3年临床结局
Clin Res Cardiol. 2025 Aug 4. doi: 10.1007/s00392-025-02719-z.
9
Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A meta-analysis of randomized controlled trials.评估前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂对心源性猝死和室性心律失常风险的潜在影响：一项随机对照试验的荟萃分析。
PLoS One. 2025 Aug 8;20(8):e0329676. doi: 10.1371/journal.pone.0329676. eCollection 2025.
10
The Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Cardiovascular Homeostasis: A Non-Systematic Literature Review.前蛋白转化酶枯草溶菌素/克新9型（PCSK9）在心血管稳态中的作用：一项非系统性文献综述
Curr Cardiol Rev. 2017;13(4):274-282. doi: 10.2174/1573403X13666170804150954.
本文引用的文献
1
Association of PCSK9 inhibitors with mortality: insights from a retrospective cohort analysis.PCSK9 抑制剂与死亡率的关联：来自回顾性队列分析的见解。
Eur Heart J Cardiovasc Pharmacother. 2024 Oct 4;10(6):505-514. doi: 10.1093/ehjcvp/pvae056.
2
Detecting Selection Bias in Observational Studies-When Interventions Work Too Fast.在观察性研究中检测选择偏倚——当干预起效过快时。
JAMA Intern Med. 2023 Sep 1;183(9):897-898. doi: 10.1001/jamainternmed.2023.2067.
3
Visualizations throughout pharmacoepidemiology study planning, implementation, and reporting.药物流行病学研究规划、实施和报告中的可视化技术。
Pharmacoepidemiol Drug Saf. 2022 Nov;31(11):1140-1152. doi: 10.1002/pds.5529. Epub 2022 Sep 9.
4
Evolocumab's Long-Term Mortality Risk Unclear Due to Shortened Follow-Up of FOURIER.由于 FOURIER 的随访时间缩短，依洛尤单抗的长期死亡率仍不明确。
Am J Cardiovasc Drugs. 2022 Jan;22(1):5-8. doi: 10.1007/s40256-021-00480-y. Epub 2021 May 19.
5
Time-related biases in pharmacoepidemiology.药物流行病学中的时间相关偏倚。
Pharmacoepidemiol Drug Saf. 2020 Sep;29(9):1101-1110. doi: 10.1002/pds.5083. Epub 2020 Aug 11.
6
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.依洛尤单抗与急性冠脉综合征后的心血管结局。
N Engl J Med. 2018 Nov 29;379(22):2097-2107. doi: 10.1056/NEJMoa1801174. Epub 2018 Nov 7.
7
Conditioning on future exposure to define study cohorts can induce bias: the case of low-dose acetylsalicylic acid and risk of major bleeding.根据未来暴露情况来定义研究队列可能会导致偏倚：低剂量阿司匹林与大出血风险的案例。
Clin Epidemiol. 2017 Nov 23;9:611-626. doi: 10.2147/CLEP.S147175. eCollection 2017.
8
Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses.指定目标试验可防止观察性分析中出现不朽时间偏倚和其他自伤性偏倚。
J Clin Epidemiol. 2016 Nov;79:70-75. doi: 10.1016/j.jclinepi.2016.04.014. Epub 2016 May 27.
9
Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes.队列研究中的不朽时间偏倚问题：以他汀类药物预防糖尿病进展为例
BMJ. 2010 Mar 12;340:b5087. doi: 10.1136/bmj.b5087.
10
The hazards of hazard ratios.风险比的危害
Epidemiology. 2010 Jan;21(1):13-5. doi: 10.1097/EDE.0b013e3181c1ea43.
Zotero 插件